MIST ▲ +2.3% - Milestone Pharmaceuticals Inc. $MIST - Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR 24-SEP-2026 08:00 AM ET